FeesSafety
Pluang+

ExlService rated Strong Buy as AI-driven growth boosts revenue and valuation potential.

Analyst Insights
24 Oct 2026
Seeking Alpha
View Source
Bullish
ExlService rated Strong Buy as AI-driven growth boosts revenue and valuation potential.

ExlService is rated a Strong Buy due to accelerating revenue growth driven by AI adoption, with its AI and data-led business now making up 61% of revenue and growing at 30% year-over-year. This growth offsets declines in legacy digital operations. The company effectively navigates regulatory challenges in industries requiring data sovereignty and liability management, enabling enterprise AI integration and high customer retention through outcome-based revenue models. Projections suggest ExlService could double in value by the end of 2027 if AI-driven growth continues and valuation multiples improve, though a downside risk of 32% exists if growth falters.

ExlService is the subject of this story, and for readers following the Technology sector, here is Pluang's market snapshot as of Oct 24, 2026 17:41 WIB: Out of 150 priced Technology-sector US stocks tradable on Pluang, 82 rose and 65 fell today. Notable movers include CRWD at USD 257.57 with a 1-day change of +8.25% and Pluang order activity showing 38% Sell / 62% Buy, ZS at USD 255.15 with +7.31% change and balanced order activity, and NET at USD 325.73 with +7.27% change and strong buy interest at 88%. The most notable figure is CRWD's 8.25% price increase today.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Autoliv remains a buy despite weak Q3 2026 with revenue and EPS missing estimates.

Autoliv remains a buy despite weak Q3 2026 with revenue and EPS missing estimates.

Autoliv reported weaker-than-expected Q3 2026 results, with both revenue and earnings per share declining year-over-year. The company faces challenges from falling global light vehicle production and rising auto loan delinquencies. However, Autoliv c...

Company Fundamentals
Neutral
4 hours ago
Meta shifts focus from costly Metaverse to promising AI-driven ad growth and commerce partnerships.

Meta shifts focus from costly Metaverse to promising AI-driven ad growth and commerce partnerships.

Meta Platforms is moving away from expensive investments in superintelligence and the Metaverse, focusing instead on AI-powered advertising and commerce partnerships that offer better monetization prospects. The company's Reality Labs losses are expe...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App